Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: A meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance

Panayiotis D. Ziakas, Petros Karsaliakos, Eleftherios Mylonakis

Research output: Contribution to journalArticlepeer-review

72 Scopus citations

Abstract

Lamivudine prophylaxis is an effective strategy in HbSAg-positive patients receiving cancer chemotherapy. Recent data indicate that a lamividune- prophylaxis strategy results in a decrease of hepatitis B virus (HBV) reactivation rates, though its effect on HBV-mortality remains equivocal. This report evaluates the benefits from this strategy among lymphoma patients and develops a management approach for patients with prolonged immunosuppression. A Medline search was conducted to retrieve published trials on HBsAg-positive lymphoma patients receiving prophylactic lamivudine during chemotherapy. Basic inclusion criterion was to report HBV-reactivation rates with and without lamivudine prophylaxis. A meta-analysis of the risk of HBV-reactivation and HBV-related mortality was conducted, and the pooled effect was calculated as risk ratio (RR). We found that lamivudine prophylaxis is associated with a significant reduction in hepatitis B virus reactivation (RR 0.21, 95%CI 0.13-0.35) and a trend in reducing HBV-related mortality (RR 0.68, 95%CI 0.19-2.49). In order to study the long-term effects of anti-HBV prophylaxis when prolonged immunosuppression is needed, we used our findings to model a decision tree. Overall survival was the main outcome used in the analysis. Rituximab maintenance in B-cell lymphomas was used as a paradigm of prolonged immunosuppression. We found that extended anti-HBV prophylaxis can improve survival rates by 2.4% in HBsAg-positive patients. If 1,000 HBsAg-positive lymphoma patients receive prophylaxis, one will die from hepatitis B virus reactivation versus 25/1,000 if no prophylaxis is administered. This effect is probably mediated through a reduction of hepatitis B virus reactivation and HBV-related mortality. The ideal antiviral agent needs to be determined.

Original languageEnglish (US)
Pages (from-to)998-1005
Number of pages8
JournalHaematologica
Volume94
Issue number7
DOIs
StatePublished - Jul 2009

Keywords

  • Hepatitis B
  • Lamivudine
  • Lymphoma
  • Mortality
  • Prophylaxis
  • Reactivation

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: A meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance'. Together they form a unique fingerprint.

Cite this